Key Takeaways
- • Pfizer has secured up to $1.5 billion from Blackstone Life Sciences to help fund development of its obesity candidate berobenatide, according to Endpoints News.
- • The financing is directed at research and development of the GLP-1 asset that Pfizer acquired through its Metsera deal, per the primary report.
- • The arrangement is a non-dilutive-style life sciences financing structure from a private investment firm, reflecting continued private capital appetite for obesity drug development.
- • The source article is partially paywalled, so detailed deal terms beyond the headline commitment are not available in the primary text.
Summary
Pfizer has secured up to $1.5 billion from the investment group Blackstone Life Sciences to help pay for the development of its obesity candidate berobenatide, according to Endpoints News. The report, published November 12, 2026, frames the commitment as funding for research and development of the GLP-1 asset that Pfizer obtained in connection with its Metsera acquisition.
The deal positions Blackstone Life Sciences as a financing partner for one of the large pharmaceutical industry's most closely watched therapeutic categories. GLP-1 based obesity treatments have drawn substantial investment from both strategic pharma companies and financial sponsors, given the size of the addressable market and the competitive pressure among developers.
The primary source is partially behind a paywall, and the available text does not include further details on the structure of the financing, milestone or repayment terms, or the timeline for clinical development. Readers seeking those specifics should consult the full Endpoints News report.
The deal positions Blackstone Life Sciences as a financing partner for one of the large pharmaceutical industry's most closely watched therapeutic categories. GLP-1 based obesity treatments have drawn substantial investment from both strategic pharma companies and financial sponsors, given the size of the addressable market and the competitive pressure among developers.
The primary source is partially behind a paywall, and the available text does not include further details on the structure of the financing, milestone or repayment terms, or the timeline for clinical development. Readers seeking those specifics should consult the full Endpoints News report.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.